BC Innovations | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
BC Week In Review | Sep 9, 2013
Company News

Galantos, Neurodyn deal

Neurodyn acquired lead Alzheimer's candidate Memogain from Galantos for an undisclosed sum. Neurodyn said Memogain completed preclinical testing and plans to start Phase I testing late this year. Memogain is a prodrug of galantamine, an...
BC Week In Review | Apr 4, 2011
Company News

J&J, Takeda sales and marketing update

Takeda launched Reminyl galantamine in Japan to treat Alzheimer's disease (AD). Takeda has co-promotion rights to the drug in Japan from Johnson & Johnson's Janssen Pharmaceutical K.K., which will supply Reminyl to Takeda. The National...
BC Week In Review | Mar 28, 2011
Clinical News

Aricept donepezil regulatory update

The U.K.'s NICE issued final guidance that allows for the broadened use of 4 Alzheimer's disease drugs that were restricted in 2006 guidance. NICE recommends the use of 3 acetylcholinesterase (AChE) inhibitors for their licensed...
BC Extra | Mar 23, 2011
Company News

NICE issues guidance backing broader use of AD drugs

The U.K.'s NICE issued final guidance that allows for the broadened use of four Alzheimer's disease drugs that were restricted in 2006 guidance. NICE recommends the use of three acetylcholinesterase (AChE) inhibitors for their licensed...
BC Week In Review | Jan 24, 2011
Clinical News

Aricept donepezil regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) that would allow for the broadened use of 4 Alzheimer's disease drugs that were restricted in 2006 guidance. NICE recommends the use of 3 acetylcholinesterase (AChE)...
BioCentury | Jan 24, 2011
Product Development

Noise-cancelling trials

MedAvante Inc. believes the reason clinical trials of psychiatric compounds so often fail has more to do with the way trials are enrolled and conducted than with the efficacy of the molecules they test. The...
BC Week In Review | Oct 11, 2010
Clinical News

Aricept donepezil regulatory update

The U.K.'s NICE issued an appraisal consultation document that would allow for the broadened use of 4 Alzheimer's disease (AD) drugs that were restricted in 2006 guidance. NICE now recommends the use of 3 acetylcholinesterase...
BioCentury | Oct 11, 2010
Finance

Regulatory Milestones

Regulatory milestones Human Genome Sciences Inc. (NASDAQ:HGSI) was off $0.16 to $29.15 last week when it said it would discontinue development of Zalbin albinterferon alfa-2b after FDA issued a complete response letter for a BLA...
BC Extra | Oct 7, 2010
Company News

NICE backs broader use of AD drugs

The U.K.'s NICE issued an appraisal consultation document that would allow for the broadened use of four Alzheimer's disease (AD) drugs that were restricted in 2006 guidance . NICE now recommends the use of three acetylcholinesterase...
Items per page:
1 - 10 of 132